JenaValve Technology Initiates Multicenter CE-Mark Study for Its Transapical TAVI System

WILMINGTON, Del. and MUNICH--(BUSINESS WIRE)--JenaValve™ Technology, Inc., a medical device company specialized in developing transcatheter valve replacement products, announced today the start of its multicenter CE-mark study. The first two implantations of its transapical TAVI system were performed by Dr. med. Hendrik Treede at the Universitäres Herzzentrum Hamburg.

Back to news